Related Experiment Video
Updated: Dec 15, 2025

Sand Fly Phlebotomus papatasi Embryo Microinjection for CRISPR/Cas9 Mutagenesis
Published on: November 17, 2020
A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene
Wen-Wei Zhang1, Subir Karmakar2, Sreenivas Gannavaram2
1Department of Microbiology and Immunology, McGill University, Montreal, QC, H3A 2B4, Canada.
Abstract:
Leishmaniasis is a neglected tropical disease caused by Leishmania protozoa transmitted by infected sand flies. Vaccination through leishmanization with live Leishmania major has been used successfully but is no longer practiced because it resulted in occasional skin lesions. A second generation leishmanization is described here using a CRISPR genome edited L. major strain (LmCen-/-). Notably, LmCen-/- is a genetically engineered centrin gene knock-out mutant strain that is antibiotic resistant marker free and does not have detectable off-target mutations. Mice immunized with LmCen-/- have no visible lesions following challenge with L. major-infected sand flies, while non-immunized animals develop large and progressive lesions with a 2-log fold higher parasite burden. LmCen-/- immunization results in protection and an immune response comparable to leishmanization. LmCen-/- is safe since it is unable to cause disease in immunocompromised mice, induces robust host protection against vector sand fly challenge and because it is marker free, can be advanced to human vaccine trials.
Related Concept Videos
CRISPR/Cas9 Genome Editing
CRISPR
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

